The American Lawyer has named Skadden M&A partner Nancy Lieberman among the publication's "Dealmakers of the Year."
Ms. Lieberman was selected for her role in Amylin Pharmaceuticals, Inc.'s agreement with Eli Lilly and Company to terminate their alliance for the diabetes drug exenatide and its subsequent $7 billion acquisition by Bristol-Myers Squibb Company.